Pathstone Family Office’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Pathstone Family Office’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-41	Closed	–	–	264
2018 Q2	$0	Hold	41	–	–	﹤0.01%	381
2018 Q1	$0	Hold	41	–	–	﹤0.01%	394
2017 Q4	$0	Buy	+41	New	+$104	﹤0.01%	224
2017 Q3	–	Sell	-41	Closed	–	–	394
2017 Q2	$0	Hold	41	–	–	﹤0.01%	725
2017 Q1	$0	Buy	+41	New	+$159	﹤0.01%	655
2016 Q4	–	Sell	-41	Closed	–	–	239
2016 Q3	$0	Hold	41	–	–	﹤0.01%	218
2016 Q2	$0	Hold	41	–	–	﹤0.01%	229
2016 Q1	$0	Buy	+41	New	+$159	﹤0.01%	193

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pathstone Family Office's AST Position: Q3 2018 in Review

Pathstone Family Office sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 41 shares.

Pathstone Family Office first reported a position in AST in Q1 2016 and held it in 8 quarters. The position peaked at $0 in Q2 2018. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

Pathstone Family Office reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
Pathstone Family Office sold 41 Asterias Biotherapeutics Inc. Series A shares in Q3 2018.
Pathstone Family Office first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2016 and held it in 8 quarters.
Pathstone Family Office's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q2 2018.
54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Pathstone Family Office's 13F filing for Q3 2018, filed 9 Nov 2018.